Join Growin Stock Community!
Beta
Back to NVO.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
net-income-chart

NVO Net Income

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

The latest data point for NVO's net income in Q1'26 shows a significant surge to $48.56B USD, marking the highest quarterly figure in the observed period and reflecting robust growth compared to the previous quarter's $26.89B USD. Over the timeframe from Q2'23 to Q1'26, net income has exhibited an overall upward trend with notable volatility, starting at $19.43B USD and climbing steadily to peaks in Q1'24 ($25.41B USD) and Q3'24 ($27.30B USD), before dipping to a low of $20.01B USD in Q3'25 amid a year-over-year decline of -26.7%. Year-over-year growth rates fluctuated between -26.7% and 67.2%, with strong positive momentum in early quarters (e.g., 61.6% in Q4'23) giving way to temporary contractions in late 2025, underscoring resilient long-term expansion driven by key inflection points like the Q1'26 rebound. This bar and line chart highlights NVO's capacity for recovery and sustained profitability in the pharmaceutical sector.